The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
A first-in-human trial of PRT12396 starts next month.
Early data are coming with the KRAS G12D degrader ARV-806.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
